SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
|
|
- Erin Barnett
- 8 years ago
- Views:
Transcription
1 1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive to improve the outcomes and quality of life for children with cancer and blood disorders. The initiative has established a strong and formal partnership between SickKids, represented by key healthcare professionals, and six countries in the Caribbean: The Bahamas, Barbados, Jamaica, St. Lucia, St. Vincent and the Grenadines and Trinidad and Tobago. Inter-professional leaders from government, hospitals and academia are working collaboratively to implement a comprehensive strategy to build sustainable capacity in the identification and management of children with cancer and blood disorders in the Caribbean. For the purposes of this Guidance Document, tumour lysis syndrome (TLS) is defined as metabolic derangement resulting from abrupt and massive breakdown of malignant cells and the release of intracellular contents into the circulation which overwhelms the patient s excretory ability. Both laboratory and clinical TLS have been described 1-4. Laboratory TLS results in high serum urate, potassium, phosphate and/or low calcium concentrations and rarely leads to clinical TLS (increased serum creatinine concentration, cardiac arrhythmia or seizure). Identification of patients at risk of developing TLS and prompt initiation of preventive interventions are critical to avoiding clinical TLS. This Guidance Document outlines the recommendations for the prevention of TLS in children diagnosed with cancer in the Caribbean. 1.1 Disclaimer This guidance document ( Guidance Document ) is intended solely for healthcare providers who are collaborators in the ( Collaborators ). The Guidance Document is a general guide to appropriate practice, to be followed only subject to the judgment of a patient's attending physician, taking into consideration all available information related to the condition of the patient and after review of the benefits and risks of the proposed course of action with the patient (if of an appropriate age) and/or the patient s parents or guardians. The Guidance Document has been specifically tailored for use at Collaborators institutions taking into consideration available health care resources and other relevant contextual factors in Collaborators countries. The Guidance Document is NOT intended for use by patients or their families and is not designed or intended to constitute medical advice or to be used for diagnosis. The Guidance Document is NOT a substitute for the personalized judgment and care provided by trained medical professionals. Every effort has been made to ensure that the information provided in the Guidance Document is accurate and in accordance with the standards accepted at the time it was created, however new research and experience may result in changes to these standards. In all cases, you, in your role as the patient s physician and the SCI lead physician for the relevant participating SCI country, are responsible for ensuring that the recommendations detailed below comply with all applicable local laws, statutes and regulations. By viewing and using any information derived from the Guidance Document, you, in your role as the patient s responsible physician, hereby waive any claims, causes of action and demands, whether in tort or contract, against any of the Collaborators (including their employees, physicians, directors and agents) in any way related Page 1 of 6
2 to use of the Guidance Document or the information derived from it. 2.0 Definitions and Abbreviations Tumour Lysis Syndrome: TLS Intravenous: IV 3.0 Clinical Practice Recommendation 3.1 Patients at risk of TLS Patients at high risk of developing TLS include children with: 3,5,8,9,11,14-16 newly diagnosed/relapsed with Burkitt lymphoma; newly diagnosed lymphoblastic lymphoma; or who present with: o a white blood cell count greater than or equal to 50 x 10 9 /L; o serum urate concentrations greater than 475 µmol/l or 7.98 mg/dl; or o pre-existing renal impairment (serum creatinine 1.5 times the upper limit of normal for age) Patients at low risk of developing TLS include children: diagnosed with: o non-haematological malignancies or o haematological malignancies with a low proliferative rate, e.g. CML in chronic phase, Hodgkin lymphoma. who present with: o a normal serum urate concentration (equal to or less than 360 µmol/l); o a white blood cell count below 20 x 10 9 /L; o no clinical evidence of significant tumour burden (e.g. no mediastinal mass, no hepato/splenomegaly); and o no pre-existing renal impairment.( serum creatinine 1.5 times the upper limit of normal for age) Other factors, which may be associated with an increased risk of developing TLS include: an elevated serum lactate dehydrogenase (LDH) concentration >2000 U/L, and dehydration. 3.2 Laboratory Investigations 3,13,15 Serum creatinine, urea, urate, potassium, sodium, phosphate, calcium, albumin, LDH concentrations and a white blood cell count with differential should be determined whenever a diagnosis of a malignancy is suspected. If Page 2 of 6
3 albumin is low, consider the need to determine serum ionized calcium concentrations. The frequency of bloodwork should be adapted according to local institution availability and anticipated turnaround time for results to be reported. It is recommended that, with the exception of LDH, these tests be repeated every 8 to 12h for patients at lower risk of TLS or every 4 to 6h for patients at higher risk of TLS until antineoplastic therapy is initiated and for at least 3 days thereafter. Bloodwork frequency may be reduced over this time as clinically determined. LDH need only be determined once at presentation. 3.3 Strategies aimed at preventing TLS Preventive strategies are aimed at minimizing laboratory TLS and preventing clinical TLS. These strategies should be continued until antineoplastic therapy has reduced the patient s tumour burden and serum creatinine and urate are stable. A period of 3 to 5 days following administration of initial antineoplastic therapy is usually required Hydration: 3,7,10,12,14,15 All patients newly diagnosed or relapsed with a malignancy that entails a risk of TLS other than those who present in acute renal failure or with oliguria should: receive IV hydration with 0.9% sodium chloride at 3L/m 2 /day (or 200mL/kg/day if the child is less than or equal to 10kg). Monitoring of serum sodium concentration (along with tumor lysis laboratory monitoring) is recommended to avoid hyper/hyponatremia, especially in the setting of impaired urine output. receive mannitol or furosemide to maintain a urine output of at least 80% of total fluid intake (i.e. at least 2.4 L/m 2 /day or 160 ml/kg/day in a patient less than or equal to 10kg). If requiring more than 3L/m 2 /day IV hydration, the urine output should be approximately 100% of total fluid intake. The maximum tolerated positive fluid balance in an afebrile patient is 600mL/m 2 /day. Diuretics should not be given if contraindicated (e.g. in the presence of hypovolemia); not receive potassium, calcium or phosphate in hydration fluids, at least initially, and have their weight assessed daily. Hydration should begin as soon as a risk of TLS is suspected, ideally, 24 to 48 hours prior to administration of antineoplastic therapy and should continue as clinically indicated Allopurinol: 3,6,14,15 Allopurinol prevents the metabolism of xanthine and hypoxanthine to uric acid by competitively inhibiting xanthine oxidase. Though allopurinol effectively prevents serum urate concentrations from increasing and decreases the incidence of uric acid nephropathy, it does not reduce the uric acid that is already present prior to administration of the drug. In addition, allopurinol results in increased concentrations of xanthine and hypoxanthine which in turn increases the risk of the precipitation of these 2 compounds, especially at higher ph; therefore, urinary alkalinization is NOT recommended. Allopurinol should be continued for at least 72 hours after the initiation of antineoplastic therapy and Page 3 of 6
4 discontinued only when serum urate concentrations are within normal limits and stable. 3, Rasburicase Rasburicase is a recombinant form of urate oxidase and catalyzes the conversion of uric acid into allantoin, a very soluble substance that is readily excreted in urine. Rasburicase reduces pre-existing uric acid. Serum urate concentrations have been shown to decrease more rapidly after rasburicase than after allopurinol administration. If available, rasburicase is recommended for the following patients: at high risk of developing TLS newly diagnosed/relapsed with leukemia or lymphoma and unable to take oral medications for physiological reasons newly diagnosed/relapsed with leukemia or lymphoma and present with significant renal impairment (serum creatinine greater than or equal to 1.5 times the upper limit normal for age) develop allergic reaction to allopurinol Rasburicase is contraindicated in patients with G6PD deficiency. If G6PD status is unknown it is suggested to send blood for G6PD assay prior to administering the first dose. If the first dose of rasburicase is administered prior to the G6PD result being available, the patient/family must be informed of the risk of hemolysis and monitored for this complication. Additional doses must be re-evaluated once the patient s G6PD status is known. Subsequent doses should be reevaluated every 24 hours. Rasburicase should not be prescribed if the serum urate is within normal limits. Rasburicase should not be given for longer than 7 days. If TLS prophylaxis is still required, allopurinol should be initiated. Antibodies to rasburicase are known to develop. Therefore, patients should be monitored for signs and symptoms of an allergic response. Patients re-treated with rasburicase following a relapse may be at increased risk of developing hypersensitivity reactions. Alkalinization is not recommended or required for the duration of rasburicase use but hydration should continue as clinically indicated. Blood samples for determination of urate concentration must be sent on ice for at least 96 hours following the administration of rasburicase. The urate concentrations of samples sent at room temperature will be reported as lower than actual. 3.5 Consideration for Nephrology Consult Consider a nephrology consult if a patient is having persistently elevated creatinine with or without decreased urine output and/or in cases of uncontrolled hyperkalemia, hyperphosphatemia and/or symptomatic hypocalcemia to assist with management. Page 4 of 6
5 4.0 References 1. Altman A. Acute tumor lysis syndrome. Seminars in Oncology 2001;28: Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clinical Lymphoma 2002;3 Suppl 1:S Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. British Journal of Haematology 2004;127: Cope D. Tumor lysis syndrome. Clinical Journal of Oncology Nursing 2004;8: Gobel BH. Management of tumor lysis syndrome: prevention and treatment. Seminars in Oncology Nursing 2002;18: Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer Journal 2005;11 Suppl 1:S Koduri PR. Alkali therapy, hyperphosphatemia, and acute tumor lysis syndrome. Medical & Pediatric Oncology 1996;26: Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contributions to Nephrology 2005;147: Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy.[see comment]. Leukemia & Lymphoma 2006;47: Pession A, Barbieri E. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contributions to Nephrology 2005;147: Seidemann K, Meyer U, Jansen P, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-hodgkin's lymphoma and B-ALL. Observations from the BFM-trials. Klinische Padiatrie 1998;210: Truini-Pittman L, Rossetto C. Pediatric considerations in tumor lysis syndrome. Seminars in Oncology Nursing 2002;18: Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clinica Chimica Acta 2003;333: Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 2008;93: Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of Clinical Oncology 2008;26: Truong TH, Beyene J, Hitzler J, et al. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome. Cancer 2007;110: van de Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Annals of Oncology 2004; 15:175-6 Page 5 of 6
6 6.0 Guidance Document Group and Reviewers Guideline adapted from SickKids Clinical Practice Guideline (2010) Management of children with acute leukemia and an elevated white blood cell count at diagnosis hyperleukocytosis. Dr. Oussama Abla, MD, Staff Physician, Division of Haematology/Oncology Alicia Koo, RPh, PharmD, Clinical Pharmacy Manager, Division of Haematology/Oncology Strategic input to guide the development of this Guidance Document was solidified from and provided by the following Caribbean hospitals: Bustamante Hospital for Children, Kingston, Jamaica University Hospital of the West Indies, Kingston, Jamaica Milton Cato Memorial Hospital, Kingstown, St. Vincent and the Grenadines Victoria Hospital, St. Lucia Queen Elizabeth Hospital, Bridgetown, Barbados Princess Margaret Hospital, Nassau, The Bahamas Eric Williams Medical Sciences Complex, Trinidad and Tobago Page 6 of 6
PATIENT PRESENTATION TREATMENT MONITORING/FOLLOW UP. Observation, normal hydration and monitoring. Low Risk 1
PATIENT PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
More informationJ Clin Oncol 26:2767-2778. 2008 by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 16 JUNE 1 2008 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review Bertrand Coiffier,
More informationTumor lysis syndrome (TLS) is a serious, lifethreatening
Case Report 70 Tumor Lysis Syndrome in Patients with Light Chain Multiple Myeloma: Report of Two Cases Hung Chang, MD; Shen-Yang Lee 1, MD; Tzung-Chih Tang, MD Tumor lysis syndrome (TLS) is a severe life-threatening
More informationDiagnosis: Appropriate diagnosis is made according to diagnostic criteria in the current Diagnostic and Statistical Manual of Mental Disorders.
Page 1 of 6 Approved: Mary Engrav, MD Date: 05/27/2015 Description: Eating disorders are illnesses having to do with disturbances in eating behaviors, especially the consuming of food in inappropriate
More informationMayo Clinic College of Medicine Pharmacy Services. Rotation Summary
Mayo Clinic College of Medicine Pharmacy Services Rotation Summary Rotation Title: PGY-2 Pediatric Hematology-Oncology Rotation Length: 3-6 weeks Primary Preceptor Name: Amanda Kuper, PharmD, BPCS, Ron
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationInformation for Childhood Cancer Survivors. Kidney Problems
Kidney problems Some chemotherapy drugs can affect the kidneys. The kidneys break down and remove many chemotherapy drugs from the body. When chemotherapy drugs get broken down, they may make products
More information5.07.09. Aubagio. Aubagio (teriflunomide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
More informationThe Eating Disorder Program The Hospital for Sick Children
The Eating Disorder Program Dear Doctor: Thank-you for your referral to the Eating Disorder Program at. The Eating Disorder Program at provides assessment and treatment for adolescents who suffer from
More informationURINARY (RENAL) STONE (NEPHROLITHOISIS) An Overview
URINARY (RENAL) STONE (NEPHROLITHOISIS) An Overview UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY PLB MBBS
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationHydration Protocol for Cisplatin Chemotherapy
Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationEducational Issues Following Treatment for Childhood Cancer
Following Treatment for Childhood Cancer Treatment for cancer during childhood or adolescence may affect educational progress due to prolonged absences or reduced energy levels that frequently occur during
More informationPHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)
1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number
More informationChapter 23. Composition and Properties of Urine
Chapter 23 Composition and Properties of Urine Composition and Properties of Urine urinalysis the examination of the physical and chemical properties of urine appearance - clear, almost colorless to deep
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationHYPERTENSION ASSOCIATED WITH RENAL DISEASES
RENAL DISEASE v Patients with renal insufficiency should be encouraged to reduce dietary salt and protein intake. v Target blood pressure is less than 135-130/85 mmhg. If patients have urinary protein
More informationOpen the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke
Open the Flood Gates Urinary Obstruction and Kidney Stones Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke Nephrology vs. Urology Nephrologist a physician who has been trained in the diagnosis
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationCalcium Folinate Ebewe Data Sheet
NAME OF THE MEDICINE Calcium folinate injection Composition Active: Calcium folinate (equivalent to 10 mg folinic acid per ml) Inactive: Sodium chloride (7.7mg/mL), qs Water for Injections. Preservative
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
Diabetic ketoacidosis in children and young people bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They
More informationSelect the one that is the best answer:
MQ Kidney 1 Select the one that is the best answer: 1) n increase in the concentration of plasma potassium causes increase in: a) release of renin b) secretion of aldosterone c) secretion of H d) release
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationGuideline for Microalbuminuria Screening
East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network
More informationReference Range: 0.5-1.6 mmol/l (arterial) 0.7-2.1 mmol/l (venous) CPT Code: 83605
LACTIC ACID Fasting, arterial specimen preferred. Please note whether arterial or venous. 0.5 ml heparinized plasma. Green top or PST must be drawn, placed on ice, and spun within 15 minutes. Immediately
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationThe Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationAcute Pancreatitis. Questionnaire. if yes: amount (cigarettes/day): since when (year): Drug consumption: yes / no if yes: type of drug:. amount:.
The physical examination has to be done AT ADMISSION! The blood for laboratory parameters has to be drawn AT ADMISSION! This form has to be filled AT ADMISSION! Questionnaire Country: 1. Patient personal
More information1 Acute Myeloid Leukaemia
1 Acute Myeloid Leukaemia 1.17 Idarubicin Pre-treatment Evaluation Morphology of blood and bone marrow aspirate. Trial patients: send 6 unstained slides to Leeds General Infirmary. Trephine biopsy and
More informationAn Introduction to the Improved FDA Prescription Drug Labeling
An Introduction to the Improved FDA Prescription Drug Labeling 1 Introduction Mary E. Kremzner, Pharm.D. CDR, U.S. Public Health Service Deputy Director, Division of Drug Information Center for Drug Evaluation
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary
More information8.301 Residential Treatment Services (RTS) Eating Disorders (Adult and Adolescent)
8.30 RESIDENTIAL TREATMENT CENTER SERVICES 8.301 Residential Treatment Services (RTS) Eating Disorders (Adult and Adolescent) Description of Services: Residential Treatment Services are provided to individuals
More informationInterpretation of Laboratory Values
Interpretation of Laboratory Values Konrad J. Dias PT, DPT, CCS Overview Electrolyte imbalances Renal Function Tests Complete Blood Count Coagulation Profile Fluid imbalance Sodium Electrolyte Imbalances
More informationAcute Care Pediatric Nurse Practitioner Certification Exam. Detailed Content Outline
Acute Care Pediatric Nurse Practitioner Certification Exam Description of the Specialty This exam is for the pediatric nurse practitioner (PNP) who has graduated from a formal acute care PNP program with
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationLymphoma Overview Joseph Leach, MD
Lymphoma Overview Joseph Leach, MD 71 year old male presents with complaints of mild fa5gue and a visible mass in the le: supraclavicular region PE demonstrates a firm easily palpable mass in the le: supraclavicular
More informationPPP 1. Continuation of a medication to ensure continuity of care
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationCyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft
INDICATIONS Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft Aplastic Anaemia (patients under 40 years) PRE-ASSESSMENT Ensure pre-transplant work-up form is complete Ensure patient has triple
More informationAll Acute Care Hospitals and End-Stage Renal Disease Clinics. Subject: Billing and Claim Completion Guidelines for Renal Dialysis Services
Indiana Health Coverage Programs P R O V I D E R B U L L E T I N BT200223 MAY 29, 2002 To: All Acute Care Hospitals and End-Stage Renal Disease Clinics Subject: Billing and Claim Completion Guidelines
More informationPHENYLEPHRINE HYDROCHLORIDE INJECTION USP
PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada
More information2.6.4 Medication for withdrawal syndrome
.6.3 Self-medication Self-medication presents a risk during alcohol withdrawal, particularly when there is minimal supervision (low level and medium level 1 settings). Inform patients of the risk of selfmedication
More informationOctober 15, 2010. Email: bcadotte@ocpinfo.com
October 15, 2010 Email: bcadotte@ocpinfo.com Ms. Barbara Cadotte Senior Policy Advisor Ontario College of Pharmacists 483 Huron Street Toronto ON M5R 2R4 Dear Ms. Cadotte: The Ontario Pharmacists' Association
More informationLothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS
MANAGEMENT OF DIABETIC KETOACIDOSIS 90 MANAGEMENT OF DIABETIC KETOACIDOSIS Diagnosis elevated plasma and/or urinary ketones metabolic acidosis (raised H + /low serum bicarbonate) Remember that hyperglycaemia,
More informationMedication Utilization. Understanding Potential Medication Problems of the Elderly
Medication Utilization Understanding Potential Medication Problems of the Elderly NICE - National Initiative for the Care of the Elderly WHAT ARE MEDICATION UTILIZATION PROBLEMS AMONG THE ELDERLY? A useful
More informationPREMEDICATIONS: Agent(s) Dose Route Schedule
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationGuidelines for Use of Controlled Substances for the Treatment of Pain
1.0 Purpose: Use of Controlled Substances for the Treatment of Pain The Physicians Advisory Committee for Controlled Substances of the Medical Society of Delaware supports the Federation of State Medical
More informationDiabetic Ketoacidosis: When Sugar Isn t Sweet!!!
Diabetic Ketoacidosis: When Sugar Isn t Sweet!!! W Ricks Hanna Jr MD Assistant Professor of Pediatrics University of Tennessee Health Science Center LeBonheur Children s Hospital Introduction Diabetes
More informationClinical Aspects of Hyponatremia & Hypernatremia
Clinical Aspects of Hyponatremia & Hypernatremia Case Presentation: History 62 y/o male is admitted to the hospital with a 3 month history of excessive urination (polyuria) and excess water intake up to
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationSTUDY GUIDE 1.1: NURSING DIAGNOSTIC STATEMENTS AND COMPREHENSIVE PLANS OF CARE
STUDY GUIDE 1.1: NURSING DIAGNOSTIC STATEMENTS AND COMPREHENSIVE PLANS OF CARE WHAT IS A NURSING DIAGNOSIS? A nursing diagnosis is a clinical judgment about individual, family, or community responses to
More informationAppendix A: Questions and Answers
Appendix A: Questions and Answers Roles and responsibilities for nursing procedures and health-related activities in school and during all school-sponsored activities is complex and, at times, difficult
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationINTRAVENOUS FLUIDS. Acknowledgement. Background. Starship Children s Health Clinical Guideline
Acknowledgements Background Well child with normal hydration Unwell children (+/- abnormal hydration Maintenance Deficit Ongoing losses (e.g. from drains) Which fluid? Monitoring Special Fluids Post-operative
More informationIMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products
Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationMichigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment of Pain
JENNIFER M. GRANHOLM GOVERNOR STATE OF MICHIGAN DEPARTMENT OF COMMUNITY HEALTH LANSING JANET OLSZEWSKI DIRECTOR Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment
More informationHow To Treat A Diabetic Coma With Tpn
GUIDELINES FOR TOTAL PARENTERAL NUTRITION (TPN) IN ADULT BONE MARROW TRANSPLANT PATIENTS TPN Indications TPN is indicated for any patient who is not expected to eat sufficiently for 3-5 days in severe
More informationGUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*
71 GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY* Ryuichi KIKKAWA** Asian Med. J. 44(2): 71 75, 2001 Abstract: Diabetic nephropathy is the most devastating complication of diabetes and is now the
More informationEXECUTIVE BLOOD WORK PANEL
EXECUTIVE BLOOD WORK PANEL Below is a list of all blood and urine testing done on the day of your Executive Medical. MALE Serum Glucose Random Serum Glucose Fasting Creatinine Uric Acid Sodium Potassium
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationLiver Function Tests. Dr Stephen Butler Paediatric Advance Trainee TDHB
Liver Function Tests Dr Stephen Butler Paediatric Advance Trainee TDHB Introduction Case presentation What is the liver? Overview of tests used to measure liver function RJ 10 month old European girl
More informationLABORATORY and PATHOLOGY SERVICES
LABORATORY and PATHOLOGY SERVICES Policy Neighborhood Health Plan reimburses participating clinical laboratory and pathology providers for tests medically necessary for the diagnosis, treatment and prevention
More informationAcquired, Drug-Induced Long QT Syndrome
Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Multiple Sclerosis Agents A. Prescriptions That Require Prior Authorization Prescriptions
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to
More informationLOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION
LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER - SHREVEPORT MEDICAL RECORDS CONTENT/DOCUMENTATION Hospital Policy Manual Purpose: To define the components of the paper and electronic medical record
More informationReview Group: Mental Health Operational Medicines Management Group. Signature Signature Signature. Review Date: December 2014
Mental Health NHS Grampian Mental Health Service Staff Guidance For The Prescribing Of Vitamin Supplementation During In-Patient Admission (Mental Health) For Alcohol Withdrawal Co-ordinators: Consultant
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationMetabolic alkalosis. ICU Fellowship Training Radboudumc
Metabolic alkalosis ICU Fellowship Training Radboudumc Case History 28-year-old male Discovered by roommate at home in bewildering state During transport by EMS possible tonicclonic seizure Arrival in
More informationHow To Treat An Alcoholic Patient
Height Weight Allergies If appropriate for patient condition, please consider the following order sets: Initiate Electrolyte Replcement: Med/Surg, Med/Surg Tele Physician Order #842 Discontinue all lorazepam
More informationBreast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail
Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast
More informationIntravenous Fluid Selection
BENNMC03_0131186116.qxd 3/9/05 18:24 Page 20 seema Seema-3:Desktop Folder:PQ731: CHAPTER 3 Intravenous Fluid Selection LEARNING OBJECTIVES By the end of this chapter, you should be able to: Describe and
More informationHow To Test For Creatinine
Creatinine is measured amperometrically. Creatinine is hydrolyzed to creatine in a reaction catalyzed by the enzyme creatinine amidohydrolase. Creatine is then hydrolyzed to sarcosine in a reaction catalyzed
More informationOSMITROL - mannitol injection, solution Baxter Healthcare Corporation
OSMITROL - mannitol injection, solution Baxter Healthcare Corporation DESCRIPTION OSMITROL Injection (Mannitol Injection, USP) is a sterile, nonpyrogenic solution of Mannitol, USP in a single dose container
More informationAcute myeloid leukaemia (AML) in children
1 61.02 Acute myeloid leukaemia (AML) in children AML can affect children of any age, and girls and boys are equally affected. Leukaemia Acute myeloid leukaemia (AML) FAB classification of AML Causes of
More informationAdult CCRN/CCRN E/CCRN K Certification Review Course: Endocrine 12/2015. Endocrine 1. Disclosures. Nothing to disclose
Adult CCRN/CCRN E/CCRN K Certification Review Course: Carol Rauen RN BC, MS, PCCN, CCRN, CEN Disclosures Nothing to disclose 1 Body Harmony disorders and emergencies Body Harmony (cont) Introduction Disorders
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More information3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP
PRESCRIBING INFORMATION 3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:
More informationLABORATORY COMPLIANCE AND MEDICAL NECESSITY
LABORATORY COMPLIANCE AND MEDICAL NECESSITY Jump to: Medical Necessity Local/National Coverage Determinations Advance Beneficiary Notice (ABN) ABN Form in English ABN Form in Spanish Annual Physician Notification
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More information8.401 Eating Disorder Partial Hospitalization Program (Adult and Adolescent)
8.40 STRUCTURED DAY TREATMENT SERVICES 8.401 Eating Disorder Partial Hospitalization Program (Adult and Adolescent) Description of Services: Eating Disorder partial hospitalization is a nonresidential
More informationTOTAL PROTEIN FIBRINOGEN
UNIT: Proteins 16tproteins.wpd Task Determination of Total Protein, Albumin and Globulins Objectives Upon completion of this exercise, the student will be able to: 1. Explain the ratio of albumin and globulin
More informationGeneral PROVIDER INITIALS: PHYSICIAN ORDERS
Height Weight Allergies If appropriate for patient condition, please consider the following order sets: Initiate Electrolyte Replcement: Med/Surg, Med/Surg Tele Physician Order #842 General Vital Signs
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationAmerican Society of Addiction Medicine
American Society of Addiction Medicine Public Policy Statement On Drug Testing as a Component of Addiction Treatment and Monitoring Programs and in other Clinical Settings [Note: ASAM also has a Public
More information